李琪,刘健,卢明瑜,马玉良,赵红,丁荣晶,刘传芬,王伟民

• 1:北京大学人民医院心脏中心

摘要(Abstract)：

目的分析药物洗脱支架(DES)再狭窄的特点及可能的相关危险因素。方法回顾性分析2006年1月1日至2012年5月1日于北京大学人民医院行冠状动脉造影复查的病例,将符合要求的病例分为支架再狭窄组217例、非支架再狭窄组420例,分析DES再狭窄的特点及可能的相关危险因素。结果糖尿病、较小的血管直径、重叠置入支架、分叉病变、钙化病变、开口病变、支架断裂与DES再狭窄相关,DES再狭窄多为局限性再狭窄,但是前降支开口病变多表现为弥漫增生性再狭窄。结论糖尿病、较小的血管直径、重叠置入支架、分叉病变、钙化病变、开口病变与支架断裂是DES再狭窄的危险因素。前降支开口病变置入DES后的再狭窄类型多为弥漫增生性,与其他类型病变不同。

关键词(KeyWords)： 药物涂层支架;冠状血管;冠状动脉再狭窄;危险因素

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李琪,刘健,卢明瑜,马玉良,赵红,丁荣晶,刘传芬,王伟民

参考文献(References)：

• [1]Morice MC,Colombo A,Meier B,et al.Sirolimus vs paclitaxel-eluting stents in de novo coronary artery lesions:the REALITYtrial:a randomized controlled trial.JAMA,2006,295:895-904.
• [2]Sato T,Ono T,Morimoto Y,et al.Differences in clinical andangiographic outcomes with different drug-eluting stents inJapanese patients with and without diabetes mellitus.J Cardiol,2012,60:361-366.
• [3]Roiron C,Sanchez P,Bouzamondo A,et al.Drug eluting stents:an updated meta-analysis of randomised controlled trials.Heart,2006,92:641-649.
• [4]Serruys PW,Silber S,Garg S,et al.Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.N Eng J Med,2010,363:136-146.
• [5]Biondi-Zoccai G,Lotrionte M,Moretti C,et al.Percutaneouscoronary intervention with everolimus-eluting stents(Xience V):systematic review and direct-indirect comparison meta-analyseswith paclitaxel-eluting stents(Taxus)and sirolimus-eluting stents(Cypher).Minerva Cardioangiol,2008,56:55-65.
• [6]Lee TT,Feinberg L,Baim DS,et al.Effect of diabetes mellituson five-year clinical outcomes after single-vessel coronary stenting(a pooled analysis of coronary stent clinical trials).Am JCardiol,2006,98:718-721.
• [7]Jukema JW,Verschuren JJ,Ahmed TA,et al.Restenosis afterPCI.Part 1:pathophysiology and risk factors.Nat Rev Cardiol,2012,9:53-62.
• [8]Kornowski R,Fort S,Almagor Y,et al.Impact of vessel size,lesion length and diabetes mellitus on angiographic restenosisoutcomes:insights from the NIRTOP study.Acute Card Care,2008,10:104-110.
• [9]Stone GW,Ellis SG,Cannon L,et al.Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patientswith complex coronary artery disease:a randomized controlledtrial.JAMA,2005,294:1215-1223.
• [10]Berenguer A,Mainar V,Bordes P,et al.Incidence andpredictors of restenosis after sirolimus-eluting stent implantation inhigh-risk patients.Am Heart J,2005,150:536-542.
• [11]Mehran R,Dangas G,Abizaid AS,et al.Angiographic patternsof in-stent restenosis:classification and implications for long-termoutcome.Circulation,1999,100:1872-1878.
• [12]Popma JJ.Strut Fractures after DES:Definitions,Frequency,Timing,Device Specificity,and Associated Clinical Events.Transcatheter Cardiovascular Therapeutics(TCT),2008.
• [13]Schofer J,Schlüter M,Gershlick AH,et al.Sirolimus-elutingstents for treatment of patients with long atherosclerotic lesions insmall coronary arteries:double-blind,randomised controlled trial(E-SIRIUS).Lancet,2003,362:1093-1099.
• [14]Kastrati A,Dibra A,Mehilli J,et al.Predictive factors ofrestenosis after coronary implantation of sirolimus-or paclitaxel-eluting stents.Circulation,2006,113:2293-2300.
• [15]Kawaguchi R,Tsurugaya H,Hoshizaki H,et al.Impact of lesioncalcification on clinical and angiographic outcome after sirolimus-eluting stent implantation in real-world patients.CardiovascRevasc Med,2008,9:2-8.
• [16]Solinas E,Nikolsky E,Lansky AJ,et al.Gender-specificoutcomes after sirolimus-eluting stent implantation.J Am CollCardiol,2007,50:2111-2116.
• [17]Li JJ.Inflammatory response,drug-eluting stent and restenosis.Chin Med J(Eng1),2008,121:566-572.
• [18]尹栋,窦克非,杨跃进,等.冠状动脉长病变患者置入雷帕霉素洗脱支架和紫杉醇洗脱支架2年临床观察.中国介入心脏病学杂志,2013,21:12-16.
• [19]Amico F,Geraci S,Tamburino C.Acute coronary syndrome dueto early multiple and complete fractures in sirolimus-eluting stent:a case report and brief literature review.Catheter CardiovascInterv,2013,81:52-56.